I was looking at the Half Yearly report, I think the R&D rebate will be quite small.
Seems like not all R&D activities qualify for the rebate (based on clinical expenses being $2m+).
FTT had $106k as a Receivable - R&D tax rebate in the balance sheet at 30 June 2018.
